LRRK2 Mutation Biomarkers for Immune Checkpoint Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The link between LRRK2 mutations and breast cancer, particularly in relation to immune checkpoint response in cancer, has been largely unexplored, despite the association between these mutations and increased breast cancer risk in PD patients, and the potential for somatic LRRK2 mutations in tumors displaying high-risk features.
Innovation Solution
A method is provided for determining the presence of LRRK2 mutations in a subject's biological sample and administering immune checkpoint therapy if such mutations are present, utilizing LRRK2 mutations as biomarkers to predict immune checkpoint response, with specific domains and types of mutations identified, including missense, frameshift, and nonsense mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint therapy is administered to all cancer patients, then some patients may benefit from treatment, but many patients will not respond and will experience unnecessary side effects and treatment costs
Solution Approach 1:
The patent extracts and focuses on a specific biomarker (LRRK2 mutation status) from the complex landscape of potential cancer biomarkers. By isolating this single genetic marker, the patent simplifies the testing system while maintaining predictive accuracy for immune checkpoint response in breast cancer patients
Solution Approach 2:
The patent changes the parameter being measured from general tumor characteristics to a specific genetic parameter (LRRK2 mutation status). This parameter change enables more precise prediction of immune checkpoint response, allowing clinicians to identify responsive patients without requiring complex multi-parameter assessment systems
2Productivity
If LRRK2 mutation testing is implemented to identify responsive patients, then treatment efficacy is improved for selected patients, but the complexity of diagnostic procedures increases
Solution Approach 1:
The patent extracts the essential predictive information from a single genetic parameter (LRRK2 mutation status) rather than requiring comprehensive genomic profiling or multiple biomarker assessments. This extraction approach maintains high treatment efficacy while minimizing diagnostic complexity
Solution Approach 2:
Instead of using complex diagnostic systems to find simple solutions, the patent inverts the approach by using a simple genetic test (LRRK2 mutation status) to guide complex treatment decisions. This inversion simplifies the diagnostic pathway while maintaining productivity in treatment outcomes
3Measurement precision
If comprehensive cancer screening is performed to identify all potential cases, then more patients are detected early, but the cost and time required for screening increases
Solution Approach 1:
The patent extracts the most predictive genetic marker (LRRK2 mutation status) from comprehensive cancer screening panels. By focusing on this single marker in high-risk populations, the patent achieves high detection accuracy without requiring time-consuming comprehensive genomic analysis
Solution Approach 2:
The patent applies targeted LRRK2 mutation testing specifically to populations with known increased risk (Parkinson's disease patients and their families) rather than universal screening. This local application of testing maintains high detection precision while minimizing time loss by avoiding unnecessary screening of low-risk individuals
Data Source
AI summary
The present disclosure describes methods and compositions involving using LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer and methods and compositions for treating cancers having certain LRRK2 mutations in a subject.